Industry experts have always known that there is a significant gap between the manufacturing cost and sales price of popular GLP-1 drugs, which are effective for both weight loss and diabetes management. Now they know also know how wide that gap really is.

Ozempic from Novo Nordisk, which sells for nearly $1,000 a month, can be manufactured for less than $5, according to a study from researchers at Yale University, King's College Hospital in London and the nonprofit Doctors Without Borders. It generally can be produced for less than various forms of insulin.

"The profit margin is immense," study author Melissa Barber, a public health economist at Yale, told "Fortune." "There should be a conversation in policy about what is a fair price."

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employee Participation
Employee-Paid
Employer-Paid